Online Resource
London :Henry Stewart Talks Ltd,
UID:
almafu_9961427330402883
Format:
1 videorecording (55 min., 23 sec.)
,
005523
Note:
Retrieved April 6, 2024, from https://hstalks.com/bs/2578/.
,
Introduction -- Outline -- Historical perspective on current drugs for TB -- TB timeline -- Timeline: drugs for TB -- Timeline: TB treatment development -- Drugs for TB (WHO guidelines 2008) (1) -- Drugs for TB (WHO guidelines 2008) (2) -- Current regimens for treatment of TB -- Latent versus active TB (1) -- Recommended treatment regimens -- Recommended 1st line regimen -- Drug dosing (1) -- Drug dosing (2) -- Dosing frequency for new TB patients -- Dosing frequency -- Practical aspects of dosing -- Sputum monitoring during treatment -- Latent versus active TB (2) -- Latent disease - treatment -- Treatment principles -- Extended multidrug therapy to cure TB (1) -- Extended multidrug therapy to cure TB (2) -- Drug profiles -- Mechanism of action of 1st line drugs (1) -- Mechanism of action of 1st line drugs (2) -- Mechanism of action of 1st line drugs (3) -- Isoniazid -- Rifampicin -- Pyrazinamide -- Ethambutol -- Streptomycin -- Limitations of current therapy and special cases -- Efficacy vs. effectiveness -- Adherence -- Summary of adverse events by drug -- Side effects (minor) -- Side effects (may be major) -- Side effects (major) -- Liver toxicity -- Management of severe liver toxicity (1) -- Management of severe liver toxicity (2) -- Management of severe liver toxicity (3) -- Drug resistance -- Special situations -- Special situations: extrapulmonary TB -- Special situations: pregnancy and children -- Special situations: liver/kidney disease -- Special situations: HIV -- Summary -- Acknowledgements.
Language:
English
| Library |
Location |
Call Number |
Volume/Issue/Year |
Availability |
